Biotech · Private company
Immunomic Therapeutics, Inc.
Track this companyFree. Adds Immunomic Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- CapecitabinePhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- ITI-1001Phase 1 · GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
- ITI-3000Phase 1 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ITI-5000 mRNA VaccinePhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- ITI-5000 MTD (Maximum Tolerated Dose)Phase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- OlaparibPhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Triple Negative Breast Cancer (TNBC)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerPHASE1 · RECRUITING · started Jul 14, 2026ClinicalTrials.gov NCT07652242 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)PHASE1 · COMPLETED · started Aug 21, 2023ClinicalTrials.gov NCT05698199 · fetched Nov 12, 2026
- Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)PHASE1 · COMPLETED · started Jun 13, 2022ClinicalTrials.gov NCT05422781 · fetched Nov 12, 2026
- RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.PHASE1 · TERMINATED · started Jan 13, 2022ClinicalTrials.gov NCT04963413 · fetched Nov 12, 2026